# Basilea Pharmaceutica

Source: https://onco.cc/companies/basilea/  
OnCo record `basilea` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Basilea is a Swiss company now focused on anti-infectives that ran phase 3 cancer trials of the FGFR inhibitor derazantinib and the tumour checkpoint controller lisavanbulin before divesting its oncology work in 2022.

## Summary

Basilea Pharmaceutica, based near Basel and listed on the SIX Swiss Exchange, markets the antifungal isavuconazole and the antibiotic ceftobiprole. Its oncology portfolio, the FGFR inhibitor derazantinib in cholangiocarcinoma and urothelial cancer and the microtubule-targeting lisavanbulin in glioblastoma, was wound down in 2022 when the company decided to concentrate on anti-infectives and sought partners for the cancer assets. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Basilea Pharmaceutica Ltd; Basilea
- Tags: ctgov-sponsor
- HQ: Allschwil
- Type: pharma
- Website: https://www.basilea.com

## Sources

- Official website: https://www.basilea.com
- ClinicalTrials.gov: trials led by Basilea Pharmaceutica: https://clinicaltrials.gov/search?lead=Basilea%20Pharmaceutica
- Wikipedia: https://en.wikipedia.org/wiki/Basilea_Pharmaceutica

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/)

---
JSON: https://onco.cc/api/v1/entities/basilea.json